Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adventrx Pharmaceuticals has announced that Mark Bagnall, a member of the company's board of directors, has joined the company as executive vice president, a newly created position, and CFO.
Subscribe to our email newsletter
As executive vice president, Mr Bagnall will work with the company’s CEO and president to define the company’s long-term strategy, help oversee internal execution of that strategy and communicate with the company’s stakeholders. Mr Bagnall most recently served as senior vice president and chief finance and operations officer of Metabolex, a biotechnology company developing therapeutics for diabetes and related metabolic disorders, positions he had held since June 2000.
Mr Bagnall will continue as a member of the company’s board of directors, but has resigned his positions on the company’s audit, compensation and nominating & governance committees, as well as his position as chair of the audit committee.
Evan Levine, CEO and president of Adventrx, said: “Mark’s expertise in the public and private sector, as well as his unique perspective as a long-time Board member, will prove invaluable as we advance our product candidates towards commercialization.”